The field has exceptional scientific expertise, experienced clinicians, specialized cancer centers, research networks, pharmaceutical capabilities, regulatory mechanisms, and philanthropic support. The problem is that they are not always connected at the points where they could have the greatest influence on whether a promising program becomes a medicine. Read more: https://www.clinicalleader.com/doc/turning-pediatric-cancer-discoveries-into-medicines-requires-better-connecti

Scientists at St. Jude Children's Research Hospital have discovered that removing the gene for Regnase-1 from engineered immune cells makes them more effective at treating relapsed osteosarcoma. Read more: https://medicalxpress.com/news/2026-08-immune-car-cell-therapy-pediatric.html

Adult childhood cancer survivors treated with anthracyclines have elevated cardiometabolic risk, emphasizing the need for structured cardiac follow-up. Read more: https://www.oncologynurseadvisor.com/news/anthracyclines-cardiometabolic-risk-childhood-cancer-survivors-treatment/

Adult survivors of Hodgkin lymphoma had nearly twice the mortality of the general United States population, according to a population-based retrospective cohort study of 20,057 long-term survivors. Read more: https://www.emjreviews.com/en-us/amj/hematology/news/hodgkin-lymphoma-survivors-face-higher-long-term-mortality/